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1. Introduction  
Diabetes and its subsequent complications present a significant challenge to our healthcare 
system. In particular, chronic diabetic wounds are a major cause of morbidity and use of 
healthcare resources in the U.S. Recent statistics reveal that 15% of diabetic patients develop 
foot and ankle chronic ulcers (Singh et al., 2005). Of these chronic wounds, 1 in 5 results in 
amputation. Further statistics reveal that 60% of nontraumatic lower-limb amputations 
occur in people with diabetes (Reiber, 2001). Chronic diabetic wounds result in a state of 
chronic inflammation about the wound site with decreased collagen and nitric oxide (NO) 
levels. The aims of these studies were to examine whether NO donor compounds will 
decrease inflammation and extracellular matrix destruction and simultaneously improve 
collagen production and wound healing. Specifically, we examined the effects of NO donors 
NOR-3 and SNOG on expression of matrix metalloproteinases (MMP)-1, -2. -8, -9 and -13, 
the inflammatory mediator interleukin-6 and collagen types I and type III by normal and 
diabetic fibroblasts under both normoxic and hypoxic states. 
2. Methods 
Prior studies by others have resulted in the development of a catalog of factors (altered 
MMP/TIMP ratio, decreased cell proliferation and migration, changes in growth factors 
[TGF-, VEGF, PDGF-BB] and cytokines [IL-1, IL-6, TNF-], extracellular matrix, 
oxygenation, and nitric oxide) which are important in normal wound healing and 
demonstrate the dysregulation that exists in chronic wounds (Chen et al., 1999; Cook et al., 
2000; Lobmann et al., 2002; Efron and Moldawer, 2004;Vandeberg et al., 2005). What was 
intriguing to us was the observation that a number of MMPs were known to be elevated in 
chronic wounds and that nitric oxide levels were quite low, but no one had drawn the 
connection that nitric oxide may regulate MMPs and promote wound healing by altering the 
MMP/TIMP ratio. By returning the MMP/TIMP ratio to near normal levels, matrix 
remodelling and growth factor regulation of the healing process could begin. The 
experiments described in this chapter were designed to examine these questions by testing 
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short-acting and long-acting NO donor compounds in fibroblast culture and in an in vivo 
skin wound repair model. We chose to evaluate enhancement of matrix production by 
measuring type I and III collagen expression and amelioration of inflammation by 
measuring interleukin-6 (IL-6) production. We have previously demonstrated that long-
acting NO donors significantly raise NO levels and reduce MMP gene expression in human 
diabetic skin fibroblast cultures (Burrow et al., 2007). 
2.1 Diabetic ulcer model 
Genetically diabetic, male C57BL/KsJ-m+/+Leprdb mice and control parental strain 
C57BL/KsJ mice were obtained from Jackson Laboratories (Bar Harbor, ME). According to 
an IACUC-approved protocol, mice were anesthetized and a 10mm full thickness wound 
was created on the dorsum. Treated mice received a single topical application of vehicle or 
500 nM (±)-(E)-ethyl-2-[(E)-hydroxyimino]-5-nitro-3-hexeneamide (NOR-3) or S-
nitrosoglutathione (SNOG) applied to the wound. The rate of wound healing was compared 
throughout the experimental period and wound area was determined by tracing the edge of 
the wound onto a glass microscope slide and determining changes in wound area by use of 
Adobe Photoshop.  
2.2 Cell culture and treatment 
Primary dermal fibroblasts were isolated from normal and diabetic mice by mincing excised 
skin samples and digesting for 2 hours in 0.20% collagenase (type I, Worthington, Freehold, 
NJ) in serum-free Dulbecco’s modified Eagle’s medium (Mediatech Inc., Manassas, VA) at 
37°C. The dissociated cells were cultured in Dulbecco’s modified Eagle’s medium with 20% 
FBS (Atlanta Biologicals, Norcross, GA) and 1% antibiotic/antimycotic supplement at 37°C 
with 100% humidity in 5% CO2 in air. Third passage fibroblasts were treated with control 
media, short-acting NOR-3, or long-acting SNOG NO donor compounds. Cells were 
incubated at 37ºC in Dulbecco’s Modified Eagle’s Medium + 20% FBS + antibiotics for 1, 3 or 
7 days. Similar experiments were carried out using human skin fibroblasts from age- and 
gender-matched non-diabetic and diabetic human subjects. Human diabetic and control 
fibroblasts (catalog no. GM00043, normal fibroblasts, and catalog no. GM01486, maturity 
onset diabetes fibroblasts) were obtained from the Coriell Institute for Medical Research 
(Camden, NJ). GM00043 cells were obtained at passage 11 and used for experiments at 
passages 14–16. GM01486 cells were obtained at passage 3 and used at passages 4–6. The 
cells were grown in T75 tissue culture flasks (Falcon BD, Bedford, MA) in minimal essential 
medium containing 15% fetal bovine serum (catalog no. 100-602; Gemini Bio-Products, West 
Sacramento, CA) and 1% penicillin-streptomycin at 37°C, following the recommended split 
ratios of 1:4 for the normal GM00043 cells and 1:3 for the diabetic GM01486 cells. For 
experiments, cells were plated in 24-well tissue culture plates (BD Biosciences, San Jose, CA) 
at a seeding density of 40,000 cells/well and cultured to confluence. The experiments were 
conducted under normoxic conditions (20% oxygen) and hypoxic conditions (2 % oxygen) 
using a Model NU-4950 CO2 incubator with the ability to accurately regulate the oxygen 
level (Nuaire Corp., Plymouth, MN). 
2.3 MMP/gelatin zymography 
MMP-2 and MMP-9 activity in control and 500 nM SNOG-treated fibroblasts were assessed 
by gelatin zymography. Samples were separated under non-reducing conditions on 10% 
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SDS-PAGE mini-slab gels co-polymerized with 150 μg/ml type I gelatin, washed in 5% 
Triton X-100, and equilibrated with collagenase assay buffer  (50 mM Tris, 200 mM  NaCl,   
5 mM CaCl2, pH 7.2) at 37°C. Counterstaining with Coomassie brilliant blue revealed MMP-
2 and -9 as cleared bands. 
2.4 MMP and collagen gene expression 
Total RNA was isolated from the non-diabetic and diabetic skin fibroblast cultures using 
TRIzol and then reverse transcribed using specific primers for MMP-2, -9 and -13, and Types I 
and III collagen. To determine the effects of NO donor on mRNA levels for each MMP, we 
performed real-time PCR analyses using 18S rRNA as the index gene, specific primers/probes 
for each MMP, and a Prism 7000 detection system (Applied Biosystems, Foster City, CA). 
2.5 Determination of growth factor and cytokine levels 
Release of cytokines and growth factors into the media of the cultures was quantified by use 
of Quantikine ELISA kits from R and D Systems. Colorimetric determination of interleukin-
6 and PDGF-BB levels were done following manufacturer’s specifications. 
3. Results 
3.1 Effects of NO donors on MMP expression 
Expression of mouse MMP-2, MMP-9, and MMP-13 was measured using real time PCR. 
MMP-2 and MMP-9 were expressed in both normal and diabetic fibroblast cultures after 1 
day of culture, but expression in the diabetic cells was 5-8 times higher than that found in 
normal (Figure 1). In contrast, MMP-13 was expressed by both cells at equivalent levels. 
When S-nitroso-N-acetylpenicillamine (SNAP), a NO donor with a half-life of 5 hours, was 
added to the cultures, a dose-dependent decrease in MMP-9 expression was observed 
(Figure 2). These results validate our previous findings in human skin fibroblasts (Burrow et 
al., 2007) and confirm that it is reasonable to expect mouse fibroblast MMP expression to be 
similar to that found with the human fibroblasts. 
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Fig. 1. Matrix metalloproteinase gene expression in control and diabetic mouse fibroblasts. 
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Fig. 2. Effect of NO donor SNAP on MMP-9 expression by control and diabetic mice 
fibroblast. 
3.2 Effects of NO donors on skin wound healing 
In the diabetic ulcer model, it can be clearly seen that wound area in the diabetic animals 
does not appreciably change over time. In contrast, normal mice mount a significant healing 
response and the wounds are virtually healed by 4 weeks. Treatment with 500 nM NO 
donor compound SNOG (Figure 3) or SNAP (data not shown) elicited a healing response in 
the diabetic animals that temporally approximated the normal healing process. 
Interestingly, normal animals treated with NO donors also displayed accelerated healing 
compared with normal controls. When 500 nM NOR-3, the fast acting donor was used, there 
was no effect on wound healing (Figure 4). 
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Fig. 3. Effect of NO donor SNOG on skin wound healing in normal and diabetic mice 
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Fig. 4. Effect of NO donor NOR-3 on skin wound healing in normal and diabetic mice 
3.3 Effects of NO donors on MMP activity determined by gelatin zymography 
Cultured fibroblasts from the skin tissue of the normal and genetically-diabetic mice were 
examined for differences in MMP activity using gelatin zymography. Clear zones indicate 
MMP activity and the results demonstrate that equivalent cell numbers of diabetic fibroblasts 
show higher MMP-9 enzyme activity as compared to normal fibroblasts (Figure 5, compare 
MMP-9 signal in lane 3 versus lane 7). When treated for 24 hours with 500 nM SNOG, a 
significant reduction in MMP-9 activity was evident for both the non-diabetic and diabetic 
fibroblast cultures (see lanes 4 and 8). There was no such effect observed for MMP-2. 
 
Fig. 5. Zymographic analysis of MMP enzyme activity before and after SNOG treatment of 
mouse fibroblast cultures. 
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3.4 Effects of NO donors on collagen gene expression 
Type I and III collagen gene expression was significantly lower under hypoxic conditions 
and in diabetic fibroblasts. Significant differences were noted in regards to collagen gene 
expression in diabetic fibroblasts and under hypoxic conditions, mimicking the in vivo 
situation of chronic wounds. Collagen type I and III gene expression in our control samples 
was decreased in diabetic fibroblasts when compared to normal fibroblasts. Also, when 
comparing normoxic to hypoxic states, expression of type I and III collagen genes was less 
in the hypoxic group. 
Type III collagen gene expression was significantly increased under normoxic conditions 
with the addition of the nitric oxide donor compound SNOG. Treatment with 1 nM SNOG, 
the long-acting NO donor, was noted to increase the levels of type III collagen expression by 
diabetic fibroblasts after three days of culture (Figure 6). In addition, the effect was dose-
dependent for the diabetic cultures. No significant effect was noted on day 1 of culture at 
any concentration tested (data not shown). In contrast to the diabetic fibroblasts, normal 
fibroblasts only responded with increased expression at the 100 nM dose. 
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Fig. 6. Effect of NO donor SNOG on Type III collagen expression by normal and diabetic 
human fibroblasts cultured for three days under normoxic conditions. 
Type III collagen gene expression was increased under hypoxic conditions with the addition 
of SNOG. Treatment with 1nM SNOG was noted to increase the levels of type III collagen 
expression by the diabetic fibroblasts on day 3 of culture (Figure 7). In addition, the effect 
was dose-dependent. However, the effect was only significant for the normal fibroblasts at 
10 nM and 100 nM SNOG-treated cultures. No significant effect was noted on day 1 of 
culture at any concentration tested (data not shown).  
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Fig. 7. Effect of NO donor SNOG on Type III collagen expression by normal and diabetic 
human fibroblasts cultured for three days under hypoxic conditions. 
Type I collagen gene expression by normal fibroblasts at day 3 was not affected by SNOG 
treatment under normoxic conditions (Figure 8). A similar trend was noted with diabetic 
cells under normoxic conditions for  type I collagen expression, except that a significant 
increase was observed with  100 nM SNOG treatment. No effect on type I collagen 
expression was noted for either normal or diabetic fibroblasts cultured for 3 days under 
hypoxic conditions (Figure 9). 
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Fig. 8. Effect of NO donor SNOG on Type I collagen expression by normal and diabetic 
human fibroblasts cultured for three days under normoxic conditions. 
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Fig. 9. Effect of NO donor SNOG on Type I collagen expression by normal and diabetic 
human fibroblasts cultured for three days under hypoxic conditions. 
However, after seven days of culture under normoxic conditions following a single addition 
of SNOG, type I collagen expression by normal and diabetic fibroblasts was found to be 
increased (Figure 10). A significant increase was observed at 1nM SNOG for the normal 
fibroblasts and  the effect was dose-dependent. Significant increases were also noted for the 
diabetic cultures, however only at the 10 and 100nM doses. Dose-dependent increases in 
type I collagen expression for normal and diabetic fibroblasts were also seen under hypoxic 
conditions (Figure 11). 
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Fig. 10. Effect of NO donor SNOG on Type I collagen expression by normal and diabetic 
human fibroblasts cultured for seven days under normoxic conditions 
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Fig. 11. Effect of NO donor SNOG on Type I collagen expression by normal and diabetic 
human fibroblasts cultured for seven days under hypoxic conditions. 
In contrast, the short-acting NOR-3 NO donor had no significant effect upon collagen gene 
expression by either normal or diabetic fibroblasts cultured under either normoxic or 
hypoxic conditions. No effect was observed under normoxic (data not shown) or hypoxic 
conditions for type III collagen expression by normal or diabetic fibroblasts cultured for 
three days in the presence of NOR-3 (Figure 12). Similarly, there was no effect on type I 
collagen expression for cultures grown under hypoxic conditions for three days (Figure 13). 
Additonally, no effects were noted on days 1 or 7 of culture (data not shown). 
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Fig. 12. Effect of NO donor NOR-3 on Type III collagen expression by normal and diabetic 
human fibroblasts cultured under hypoxic conditions. 
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Fig. 13. Effect of NO donor NOR-3 on Type I collagen expression by normal and diabetic 
human fibroblasts cultured under hypoxic conditions. 
3.5 Effects of NO donors on interleukin-6 production 
The nitric oxide donor SNOG reduced IL-6 production by normal and diabetic skin 
fibroblasts grown under normoxic conditions and hypoxic conditions. At the control (0 nM) 
concentration, diabetic cells show significantly greater production of IL-6 than normal 
fibroblast cultures. The long-acting nitric oxide donor  SNOG  dose-dependently reduced 
IL-6 production for diabetic fibroblasts cultured either under normoxic conditions (Figure 
14) or hypoxic conditions (Figure 15). In contrast, normal fibroblasts only demonstrated an 
effect at the highest dose of NO donor under either normoxic or hypoxic conditions. 
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Fig. 14. Effect of NO donor SNOG on IL-6 production by normal and diabetic human 
fibroblasts cultured under normoxic conditions.  
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Fig. 15. Effect of NO donor SNOG on IL-6 production by normal and diabetic human 
fibroblasts cultured under hypoxic conditions. 
The short-acting NO donor NOR-3 had no significant effect upon IL-6 production in either 
normal or diabetic fibroblasts cultures grown under either normoxic conditions (Figure 16) 
or hypoxic conditions (Figure 17). 
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Fig. 16. Effect of NO donor NOR-3 on IL-6 production by normal and diabetic human 
fibroblasts cultured under normoxic conditions. 
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Fig. 17. Effect of NO donor NOR-3 on IL-6 production by normal and diabetic human 
fibroblasts cultured under hypoxic conditions. 
3.6 Effects of NO donors on PDGF-BB production 
Nitric oxide donor treatment had no effect on PDGF-BB production by normal fibroblasts 
grown under normoxic or hypoxic conditions. Under normoxic conditions, the normal cells 
produced twice as much PDGF as the diabetic cells, whereas in the hypoxic environment the 
normal cells produced five times as much PDGF (data not shown). Neither of the nitric 
oxide donors tested had any significant effect on PDGF production in either of the 
environmental conditions that were statistically significant. 
3.7 Summary 
MMP-9 and interleukin-6 expression is higher, and type I and type III collagen expression is 
lower, in diabetic fibroblasts in both normoxic and hypoxic states as compared to normal 
fibroblasts. With the addition of the NO donor with the relatively long half-life (SNOG), 
MMP-9 gene expression and enzyme activity were decreased. Additionally, production of 
the inflammatory cytokine interleukin-6 was decreased by increasing NO levels with SNOG. 
Concurrently, type I and type III collagen expression were increased. Treatment with SNOG 
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resulted in a significant effect upon collagen type III production in a dose-dependent 
fashion in both normal and diabetic fibroblasts under both normoxic and hypoxic states. In 
diabetic fibroblasts, under a normoxic state, the effect did not become significant until the 
1nM SNOG-treated cells on day 3, and continued at the 10nM and 100nM concentrations on 
days 3 and 7. The effect upon collagen type III production in diabetic fibroblasts, under a 
hypoxic state, was found to be significant at the 1nM, 10nM, and 100nM in SNOG-treated 
cells on days 3 and 7. The effect of the addition of SNOG to both normal and diabetic 
fibroblasts under both normoxic and hypoxic states also results in a significant increase in 
collagen type I production in a dose dependent fashion. The effect in diabetic fibroblasts, 
under a normoxic state, was noted to be significant at the 100nM concentration of the SNOG 
donor compound on day 3. The effect in diabetic fibroblasts, under a hypoxic state, was 
found to be significant at the 10nM and 100nM level on day 7. The addition of NOR-3 had 
no significant effect upon the production of type I or III collagen in normal or diabetic 
fibroblasts. 
4. Conclusion 
Chronic diabetic wounds present a significant challenge to healthcare providers and 
resources. Significant amounts of time, money and resources have gone into prevention and 
treatment of these wounds. However, despite these efforts, chronic wounds continue to pose 
a serious problem. This has led researchers to focus more on understanding the molecular 
organization and function of normal wound healing and how this process is altered in 
chronic diabetic wounds. This is a very complex process that occurs through a series of 
highly integrated interactions between a multitude of varying cell types, growth factors, and 
cytokines. In diabetics, these wound healing interactions are disrupted and the process of 
wound healing seems to be locked in a perpetual state of chronic inflammation.  
In diabetic wound healing, a physiologic state consistent with decreased nitric oxide (NO) 
levels results, leading to an impaired inflammatory response, decreased collagen 
production, and decreased wound-breaking strength (Witte et al., 2002). Prior studies have 
also revealed the MMP levels are significantly elevated in chronic diabetic wounds, thus 
creating an imbalance in matrix breakdown and release of growth factors that are important 
for normal wound healing (Wysocki et al., 1993; Trengove et al., 1999; Lobmann et al., 2002). 
Chronic diabetic wounds appear to be physiologically trapped in the inflammatory stage of 
wound healing and nitric oxide may promote normal healing by selectively reversing 
dysregulated factors (e.g.: localized ischemia, cell proliferation, MMP/TIMP ratio, growth 
factors/ cytokines, matrix synthesis) which prevent progression to the reepithelialization 
phase of wound healing. Additionally, nitric oxide may play a larger role in diabetic foot 
problems as low levels of endothelial nitric oxide synthase, an enzyme responsible for nitric 
oxide production, is associated with bone fractures (Loveridge et al., 2002) and Charcot 
neuroarthropathy (La Fontaine et al., 2008).  
Prior studies have shown that introduction of a NO donor can improve wound healing 
(Shabani et al., 1996; Bohl-Masters et al., 2002). The mechanism(s) responsible for NO-
induced healing remains unclear. Our studies reveal significant differences in the levels of 
MMP-9, NO synthetases, PDGF-BB, interleukin-6 and types I and III collagen in normal 
www.intechopen.com
 
Global Perspective on Diabetic Foot Ulcerations 
 
196 
and diabetic fibroblasts. With the addition of NO donor compounds, the levels of 
extracellular matrix-degrading MMP-9 and inflammatory mediator interleukin-6 were 
decrease in skin fibroblast cultures. NO donors stimulated type I and III collagen 
expression in both normal and diabetic fibroblasts and under both normoxic and hypoxic 
states. Thus, the results of this study combined with previous studies involving chronic 
diabetic wounds, the potential exists to develop a topical media to apply to chronic 
wounds that would introduce these NO donors to the wound site to improving the 
healing potential of these wounds. 
Although it is known that diabetic patients display impaired wound healing, the mechanism 
for this impairment is not fully understood. Because fibroblasts are essential for dermal 
wound repair, the current study compared the in vitro behavior of human dermal 
fibroblasts. It has been reported that fibroblasts from diabetic wounds continue to display 
impaired proliferation even when taken out of their in vivo diabetic environment and 
cultured in vitro (Burrow et al., 2007; Loot et al., 1999; Hehenberger et al., 1998). Therefore, 
identical tissue culture conditions should not obscure differences between our experimental 
groups. 
Diabetic cells when compared to normal cells demonstrated a decreased gene expression in 
types I & III collagen, eNOS and iNOS, and PDGF-BB, with an increased production of IL-6. 
Within the hypoxic condition the expression of types I & III collagen, eNOS and iNOS and 
PDGF-BB were further reduced in both the diabetic and normal cells, whereas the IL-6 
production was only significantly increased within the diabetic fibroblasts. With the 
treatments of the NO donors, it was demonstrated that when evaluating the types I & III 
collagen and eNOS and iNOS only SNOG was seen to have an effect on either type, with its 
most profound effect on type III collagen in both environmental conditions. The IL-6 
production was only decreased by the long-acting NO donor SNOG. Neither NO donor 
demonstrated a significant effect upon PDGF-BB production.  
In 2005, we demonstrated that the addition of the NO donor SNAP to skin wounds in a 
diabetic mouse model significantly increased the rate and extent of wound healing (Stehly et 
al., 2005). The wound healing rates in the diabetic treatment groups approximated the 
normal mice. In a study by Bohl-Masters et al., 2002, a polyvinyl alcohol hydrogel 
impregnated with NO donor was used to increase the local NO concentration in a wound 
healing model in diabetic and normal mice. They found that wound healing in the NO 
donor-treated diabetic mice was either the same or slightly less than in the control group. 
However, the quality of granulation tissue was much improved in the presence of nitric 
oxide donor. 
NO has been shown to be significantly reduced in chronic ulcers. Impaired healing of 
diabetic wounds is thought to be related to diminished NO production (Witte et al., 2002; 
Schaffer et al., 1997). Because the level of NO in chronic wounds is low, and elevation of 
NO enhances wound healing, a number of other approaches have been tried to deliver 
NO therapeutically. Studies using compounds such as L-arginine (Shi et al., 2003), vitamin 
B12 (Bauer et al., 1998), and multivitamin therapy using a combination of folic acid, 
vitamin B6, and vitamin B12 (Boykin et al., 2005) have reported concomitant increases in 
wound tissue NO level and healing. The latter study demonstrated that serum 
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homocysteine, an inhibitor of NOS, is elevated in patients with chronic wounds; with 
multivitamin therapy, this inhibitor is decreased and associated with enhanced healing. 
Both of these approaches employ systemic delivery of the compounds to raise NO, but do 
not involve a local targeted delivery of NO directly into the wound site. Very few 
investigations have sought to deliver NO directly into wounds. For example, one study 
using a NO-modified polyvinyl alcohol hydrogel effectively healed cutaneous wounds in 
diabetic mice (Bohl-Masters et al., 2002). Increased production of extracellular matrix 
molecules was noted in this study, but no attempt was made to measure changes in MMP 
activity. Other approaches used to deliver NO to the wound have used linear 
polyethyleneimine/NO adducts (Bauer et al., 1998) and delivery of iNOS naked DNA via 
a collagen sponge (Thornton et al., 1998). Both of these approaches reported toxic effects 
related to the delivery of excessive levels of NO to the wound, suggesting the need for a 
more finely controlled transient release of NO. The longer-acting NO donor compounds, 
SNAP and SNOG, used in the current study, and similar cell-permeable compounds 
which produce transient increases in tissue NO concentration, should provide a means of 
optimizing the therapeutic effect. NO donor compounds may ultimately provide a new 
therapeutic tool for the treatment of diabetic foot wounds.  
The purpose of this study was to assess the effect that NO donor compounds would have 
upon the production of type I and type III collagen production in diabetic fibroblasts both in 
normoxic and hypoxic (representative of chronic diabetic wounds) states. Prior studies have 
mainly focused upon the effect in normal fibroblasts under normoxic conditions. This study 
demonstrated that collagen type I and type III production was decreased in diabetic 
fibroblasts under both normoxic and hypoxic states when compared to normal fibroblasts 
without the addition of NO donor compounds. Thus, providing a catalyst to increase the 
amount of type I and type III collagen could potentially improve wound healing in diabetic 
chronic wounds.  
To examine the time dependence of NO action in wound healing, this study utilized a 
shorter acting NO donor compound (NOR-3) and a relatively long-acting NO donor, SNOG, 
to assess their effects upon collagen production. Through the introduction of these agents in 
this study, significant increases in collagen type I and type III production were observed. In 
fact, the effect of the SNOG NO donor compound upon type III collagen production in 
diabetic fibroblasts demonstrated a significantly greater dose dependent effect than that 
observed in normal fibroblasts. Type I collagen levels were also significantly increased with 
the addition of the SNOG NO donor compound in both diabetic and normal fibroblasts. 
However, the dose dependent relationship for collagen type I production was essentially the 
same for both normal and diabetic fibroblasts. 
The short acting NO donor compound (NOR-3), was not found to have any significant effect 
upon collagen type I or III production in diabetic fibroblasts. This finding, along with 
previous findings with the use of NOR-3 potentially indicate that relatively longer-acting 
NO donor compounds are more effective at NO and collagen production in diabetic 
fibroblasts. Thus, using a relatively longer-acting NO donor compound could potentially 
expose the chronic wound to longer duration of NO further increasing the wound healing 
potential and being present throughout more of the wound healing stages. 
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The results observed in this study are very encouraging in regards to possible future 
treatment of chronic diabetic wounds. By studying the effects of these NO donor 
compounds in diabetic fibroblasts under normoxic and hypoxic states we have been able to 
create an environment more closely resembling a chronic wound state in human diabetic 
patients. From the results of this and other studies in our laboratory we now have the 
potential to develop a topical treatment for chronic diabetic wounds based upon optimal 
delivery of NO to assist with wound healing. Preliminary studies are currently being 
performed examining SNOG attachment and release from both collagen-based and 
hydroxyapatite-based scaffolds. The goals of these studies are to develop new types of 
synthetic graft materials for the treatment of diabetic skin and bone wounds respectively. 
Future research will be directed toward development and optimization of these and other  
NO delivery systems for the treatment of wounds and other diabetic complications.  
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